Replies to post #170499 on Biotech Values

[DewDiligence]

India’s Supreme Court rules in favor of MYL/Biocon re Herceptin FoB:

http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/delhi-hc-gives-biocon-mylan-green-light-to-market-blockbuster-biosimilar-for-three-cancers/articleshow/57451618.cms

The Court made two concessions: i) MYL/Biocon can now include Roche’s data for branded Herceptin in the FoB product label; and ii) the FoB is approved for all three of branded Herceptin’s indications.